Advanced

AJNR - American Journal of Neuroradiology

Published ahead of print on December 26, 2008
doi: 10.3174/ajnr.A1376

This Article Full Text Full Text (PDF) All Versions of this Article: ajnr.A1376v1 30/3/492    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hauck, E.F. Articles by Samson, D. Search for Related Content PubMed PubMed Citation Articles by Hauck, E.F. Articles by Samson, D.

American Journal of Neuroradiology 30:492-495, March 2009
© 2009 American Society of Neuroradiology

INTERVENTIONAL

Preoperative Embolization of Cerebral Arteriovenous Malformations with Onyx

E.F. Hauck^a, B.G. Welch^a,b, J.A. White^a, P.D. Purdy^b, L.G. Pride^b and D. Samson^a

^a Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Tex
^b Department of Neuroradiology, University of Texas Southwestern Medical Center, Dallas, Tex

Please address correspondence to Erik F. Hauck, MD, PhD, Department of Neurosurgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390; e-mail: erik.hauck{at}utsouthwestern.edu

BACKGROUND AND PURPOSE: Preoperative embolization facilitates the surgical management of complex cerebral arteriovenous malformations (cAVMs). This analysis aims to investigate the risks for preoperative cAVM embolization with Onyx.

MATERIALS AND METHODS: We retrospectively analyzed clinical data of all patients who underwent embolization with Onyx as a preoperative treatment of cAVMs at our institution since 2005 (US Food and Drug Administration [FDA] approval). Patients with arteriovenous fistulas were excluded. A total of 107 patients were treated for cAVMs during the study period. Of those patients, 41 underwent cAVM embolizations with Onyx in 82 procedures.

RESULTS: After the embolization, the cAVM diameter was reduced from 3.71 ± 1.55 cm to 3.06 ± 1.89 cm (P < .05). Median volume reduction was 75%. Complete occlusion with embolization alone was achieved in 4 (10%) cAVMs. The recurrence rate for completely occluded cAVMs was 50% (2 patients). A total of 71% of the 41 patients treated with Onyx underwent surgery, and 15% underwent radiosurgery. There were 9% who have not yet received definitive treatment of their residual cAVMs. A new permanent neurologic deficit occurred in 5 patients (6.1% per procedure or 12.2% per patient).

CONCLUSIONS: A considerable risk for a permanent neurologic deficit remains for cAVM embolization with Onyx. The risk has to be carefully weighted against the benefit of volume reduction in the treatment of cAVMs.

This article has been cited by other articles:

				M. J. Gounis, M. J. De Leo III, and A. K. Wakhloo Advances in Interventional Neuroradiology Stroke, February 1, 2010; 41(2): e81 - e87. [Full Text] [PDF]